Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Safety issue puts daclizumab in doubt for MS
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Sanofi withdraws Campath in US and EU
Genzyme's Lemtrada resubmission accepted for review by FDA
The history of the oxazaphosphorine cytostatics.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Food and Drug Administration Approval Letter for Alemtuzumab
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Mitochondrial approaches for neuroprotection.
White matter astrocytes in health and disease.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.

Pages